Edwards Lifesciences Corp (EW) Price

The P/E ratio of Edwards Lifesciences Corp is 11.2312

The current price of EW is $74.42, it has increased 0.01% in the last trading day.

Edwards Lifesciences Corp belongs to Health Care industry and the sector is Health Care

Edwards Lifesciences Corp's current market cap is $43.6B

According to wall street analysts, 34 analysts have made analyst ratings for Edwards Lifesciences Corp, including 10 strong buy, 17 buy, 15 hold, 0 sell, and 10 strong sell

Updated: Mon, 15 Sep 2025 08:45:46 GMT

The stock is exhibiting short-term bearish pressure within a longer-term uptrend, pulling back from resistance levels.

The current price of $77.57 is trading below its 50-day moving average of approximately $78.83, indicating a loss of short-term momentum. However, it remains above the 200-day moving average of $74.57, suggesting the long-term uptrend is still intact. The daily MACD has registered a bearish crossover, and the RSI is weakening, pointing towards potential for further downside towards the support level near $74.25 before buyers may step back in.

Strong sales growth in the TMTT segment and upgraded TAVR guidance are fueling positive business momentum.

• TMTT Surge: Sales in the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment grew an explosive 61.9% in Q2 2025, driven by strong adoption of the PASCAL and EVOQUE systems.
• TAVR Strength: Guidance for the core Transcatheter Aortic Valve Replacement (TAVR) business was raised to 6-7% growth, signaling renewed momentum in its largest market.
• Beating Expectations: Analysis suggests a 45% probability that the company will slightly beat revenue expectations in the upcoming quarters, validating management's confident outlook.

A robust pipeline focused on expanding the addressable markets for TAVR and TMTT provides significant long-term growth drivers.

• TAVR Market Expansion: Recent FDA approval for TAVR use in asymptomatic patients represents a multi-year tailwind, with the ongoing PROGRESS trial potentially opening the market to moderate aortic stenosis patients next.
• TMTT Advancements: The upcoming European launch of the SAPIEN M3 mitral valve, with a pivotal trial readout expected in late 2025, is a key catalyst for the TMTT segment.
• Anticipated US Approval: Approval for the SAPIEN M3 valve in the United States is anticipated in the first half of 2026, which could further accelerate growth.

The Federal Trade Commission's (FTC) decision to block the acquisition of JenaValve is the most significant near-term risk facing the company.

• Market Entry Blocked: The FTC challenge creates a major hurdle for Edwards' planned entry into the Aortic Regurgitation (AR) market, a key part of its growth strategy.
• Lengthy Legal Battle: The dispute is expected to involve a prolonged legal battle, with a potential final determination not expected until the end of Q1 2026.
• Sentiment Dampener: This regulatory risk is a primary factor weighing on investor sentiment, creating headline risk that overshadows strong operational performance.

Ownership is concentrated in stable, passive index funds, providing a solid foundation, though a key active manager recently trimmed its position.

• High Institutional Conviction: Institutions hold a commanding 79% to 88% of the company's stock, signaling deep conviction from sophisticated investors.
• Passive Dominance: The largest holders are broad-market index funds from firms like Vanguard, which provides a stable shareholder base and reduces volatility.
• Active Manager Signal: The actively managed Vanguard Health Care Fund recently reduced its significant holding, a critical data point for investors to monitor as it could signal a shifting thesis from a well-informed manager.

Recent selling by executives is consistent and pre-planned, suggesting it is not related to a negative view of the company's prospects.

• Executive Sales: Corporate officers, including the Global President of TAVR, have sold shares throughout 2025.
• Pre-Arranged Plans: These transactions were executed under pre-arranged Rule 10b5-1 trading plans, which are set up in advance for personal financial planning and diversification.
• Neutral Signal: Because the sales are automated and not based on spontaneous decisions, they are considered a neutral signal regarding the company's near-term outlook.

The company's inclusion in major medical device ETFs provides a stable shareholder base and links its performance to broader sector trends.

• Core Holding: EW is a key component in specialized ETFs like the iShares U.S. Medical Devices ETF (IHI) and the SPDR S&P Health Care Equipment ETF (XHE).
• Reduces Volatility: This heavy ownership by passive funds, which buy and hold based on index rules, helps create a support floor for the stock and reduces turnover.
• Sector-Tied Performance: Inclusion in these ETFs insulates the stock from some company-specific news flow and ties its performance more closely to broader investment themes in the healthcare equipment sector.

Trading activity is healthy and consistent, indicating stable investor interest, while low short interest suggests a lack of strong bearish conviction.

• Healthy Liquidity: The recent 20-day average volume is 3.68 million shares, reflecting a consistent daily turnover rate of approximately 0.63%.
• Slight Activity Dip: Current volume is slightly below the 60-day average, indicating a minor decrease in trading activity during the recent consolidation period.
• Low Short Interest: Short interest stands at a modest 1.5% of the float, which is below the peer group average and suggests the stock is not a primary target for short-sellers.

The stock exhibits a favorable risk-adjusted return profile, generating strong performance without subjecting investors to excessive volatility.

• Market-Like Volatility: With a 12-month Beta of approximately 1.03, the stock's volatility is almost perfectly in line with the broader market.
• Efficient Returns: A solid 1-year Sharpe Ratio between 0.74 and 0.91 indicates the stock has generated efficient returns for the total risk taken.
• Downside Protection: A high 1-year Sortino Ratio of 1.51 demonstrates that the stock has been highly effective at generating returns without significant negative price swings.

Wall Street analysts are broadly bullish on Edwards Lifesciences, with the consensus price target implying significant upside from the current price.

The consensus "BUY" recommendation is supported by 27 of 34 analysts rating the stock as either a "Buy" or "Strong Buy". The mean price target of $89.98 represents a potential upside of over 15% from the current price.

Key events to monitor include regulatory rulings, clinical trial data, and new product approvals, which could serve as major catalysts or risks.

Edwards Lifesciences presents a classic case of operational excellence versus external headwinds. The company is firing on all cylinders, with its TMTT division emerging as a powerful new growth engine alongside a reinvigorated TAVR franchise that continues to expand its addressable market. This fundamental strength is reflected in its premium valuation and strong analyst support.

However, the stock's momentum is currently capped by the significant regulatory uncertainty of the FTC's challenge to the JenaValve acquisition. This issue creates headline risk that prevents the market from fully pricing in the company's growth prospects. The current technical pullback is a reflection of this consolidation. A positive resolution to the FTC case or a major clinical trial success, like the SAPIEN M3 readout, will likely be required to break the stock out of its current range and unlock the next leg up.